66 results
8-K
EX-99.1
AUPH
Aurinia Pharmaceuticals Inc
15 Feb 24
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
6:06am
approval commitments, manufacturing and packaging commercial drug supply, funding its commercial infrastructure, advancing its LUPKYNIS (voclosporin
8-K
EX-99.1
AUPH
Aurinia Pharmaceuticals Inc
2 Nov 23
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
6:01am
to fund its operations, which include funding commercial activities, such as FDA related post approval commitments, manufacturing and packaging
8-K
EX-99.1
fxd8kel1ymhq5z
3 Aug 23
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
6:03am
8-K
EX-99.1
yon dg35u
4 May 23
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
6:06am
8-K
EX-99.1
5evxswwvmm65ant00g7d
3 Nov 22
Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results
6:04am
8-K
EX-99.1
w57w8kktz6
4 Aug 22
Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results
6:07am
8-K
EX-99.1
6k3rps98hh7d6rc4
10 May 22
Aurinia Reports First Quarter 2022 Financial and Operational Results
6:06am
8-K
EX-99.1
guxndgf kuvy
28 Feb 22
Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates
6:08am
S-3ASR
EX-1.2
4cylfxwkhv4cl rw
19 Nov 21
Automatic shelf registration
5:04pm
8-K
EX-99.1
i50uqoz77cmw6yq147
3 Nov 21
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates
12:00am